| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 04/29/2004 | CA2502397A1 Treatment for reactive arthritis or bursitis |
| 04/29/2004 | CA2502355A1 Halogenated selective androgen receptor modulators and methods of use thereof |
| 04/29/2004 | CA2502284A1 Bisphosphonates for the treatment of antheroscleorosis and devices comprising them |
| 04/29/2004 | CA2502227A1 Nitrone compounds, pharmaceutical compositions containing the same and methods for treating inflammation and neuropathic pain |
| 04/29/2004 | CA2502218A1 Composition with stabilized redox properties and method of stabilization of redox properties |
| 04/29/2004 | CA2502211A1 Azo compounds for type i phototherapy |
| 04/29/2004 | CA2502209A1 Methylene-bridged selective androgen receptor modulators and methods of use thereof |
| 04/29/2004 | CA2502064A1 Benzopyranone compounds, compositions thereof, and methods for treating or preventing cancer |
| 04/29/2004 | CA2502032A1 Use of norepinephrine reuptake modulators for preventing and treating vasomotor symptoms |
| 04/29/2004 | CA2502027A1 A method of treating vasomotor symptoms comprising a compound having norepinephrine reuptake inhibitor activity and 5-ht2a antagonistic activity |
| 04/29/2004 | CA2502021A1 Use of norepinephrine reuptake modulators for preventing and treating vasomotor symptoms |
| 04/29/2004 | CA2501999A1 Compositions and methods for inducing osteogenesis |
| 04/29/2004 | CA2501959A1 Therapeutic treatment |
| 04/29/2004 | CA2501943A1 Orally administered peptides synergize statin activity |
| 04/29/2004 | CA2501942A1 Dihydroartemisinin and dihydroartemisitene dimers as anti-cancer and anti-infective agents |
| 04/29/2004 | CA2501936A1 Selective cytokine inhibitory drugs for treating myelodysplastic syndrome |
| 04/29/2004 | CA2501798A1 Preparation of triazospiro compounds |
| 04/29/2004 | CA2501797A1 Treating obesity with selective androgen receptor modulators |
| 04/29/2004 | CA2501556A1 Remedy for hormone-dependent cancer |
| 04/29/2004 | CA2501538A1 Carbohydrate based anti-bacterials |
| 04/29/2004 | CA2501418A1 Novel compounds |
| 04/29/2004 | CA2501381A1 Method of administering bisphosphonates |
| 04/29/2004 | CA2501298A1 Method of modifying the release profile of sustained release compositions |
| 04/29/2004 | CA2501201A1 Gastric acid secretion inhibiting composition |
| 04/29/2004 | CA2501093A1 Combinations of benzodithiazoles and cox-2 inhibitors for the treatment of pain |
| 04/29/2004 | CA2500417A1 Neurotrophic factor production promoter |
| 04/29/2004 | CA2500083A1 Tetrahydroquinoline derivatives as crth2 antagonists |
| 04/29/2004 | CA2498095A1 Method for extracting a natural mixture of conjugated equine estrogens that is depleted of non-conjugated lipophilic compounds |
| 04/29/2004 | CA2497780A1 Pharmaceutical composition for treating pain comprising oxicarbazepine, or derivatives thereof, and cox2 inhibitors |
| 04/29/2004 | CA2497262A1 Buccal polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system |
| 04/29/2004 | CA2496633A1 Diagnostic probes and remedies for diseases with accumulation of prion protein, and stains for prion protein |
| 04/28/2004 | EP1413589A1 Polymers for oral use and compositions for oral use |
| 04/28/2004 | EP1413582A1 Dimeric pyrrolobenzodiazepines |
| 04/28/2004 | EP1413581A1 Rapamycin derivatives |
| 04/28/2004 | EP1413580A1 Furanone derivatives as inhibitors of Cathepsin S |
| 04/28/2004 | EP1413579A1 Imidazoline derivatives, process for the preparation thereof and pharmaceutical compositions containing them |
| 04/28/2004 | EP1413576A2 Substituted imidazole derivatives having agonist-like activity at alpha 2B or 2B/2C adrenergic receptors |
| 04/28/2004 | EP1413332A1 Use of 2,5-dihydroxybenzenesulphonic acid derivatives in the production of a medicament used to potentiate the effect of other drugs in the treatment of erectile dysfunction |
| 04/28/2004 | EP1413331A2 Combinations of peroxisome proliferator-activated receptor (PPAR) activator(s) and sterol absorption inhibitor(s) for vascular indications |
| 04/28/2004 | EP1413315A1 Sustained-release medicines |
| 04/28/2004 | EP1413314A1 Medicinal compositions |
| 04/28/2004 | EP1413313A1 DIAGNOSIS AND TREATMENT OF INSULIN−DEPENDENT DIABETES MELLITUS AND INSULITIS |
| 04/28/2004 | EP1413309A1 Drugs for ameliorating postcibal hyperglycemia |
| 04/28/2004 | EP1413308A1 Hypoglycemic agent |
| 04/28/2004 | EP1413307A1 Therapeutically active levorotatory and dextrorotatory 1-(4-chlorophenyl)phenylmethyl piperazines |
| 04/28/2004 | EP1413305A1 Aryl (or heteroaryl) azolylcarbynol derivatives for the treatment of urinary incontinence |
| 04/28/2004 | EP1413304A1 Use of combination of carnitine and lipoic acid for restoring mitochondrial function |
| 04/28/2004 | EP1413303A1 Swine growth promoters and method of promoting swine growth |
| 04/28/2004 | EP1413302A2 Substituted guanidines for the treatment of pain |
| 04/28/2004 | EP1413301A1 Antifungal medicaments comprising arylamidine derivatives |
| 04/28/2004 | EP1413300A1 Pyrimidinium-guanidiniminoethylphenyl-guanidinoalkyl-amines and guanidiniminoethylphenyl-guanidinoalkylamines as pharmaceutically active new substances |
| 04/28/2004 | EP1413299A2 Use of deprenyl analogues to maintain, prevent loss, or recover nerve cell function |
| 04/28/2004 | EP1413295A1 Sustained release composition for oral administration of drugs |
| 04/28/2004 | EP1413294A1 COMPOSITIONS CONTAINING SUSTAINED−RELEASE FINE GRAINS FOR TABLETS QUICKLY DISINTEGRABLE IN THE ORAL CAVITY AND PROCESS FOR PRODUCING THE SAME |
| 04/28/2004 | EP1413293A1 Ointment for combatting fungi |
| 04/28/2004 | EP1413291A1 Use of 5-Cholesten-3 beta,25-diol-7-one for the treatment of dry skin or scalp |
| 04/28/2004 | EP1413201A2 Use of neuronal sodium channel antagonists for the control of ectoparasites in homeothermic animals |
| 04/28/2004 | EP1412757A2 Method for identification of proteins from intracellular bacteria |
| 04/28/2004 | EP1412515A2 Treatment of cns disorders using d-amino acid oxidase and d-aspartate oxidase antagonists |
| 04/28/2004 | EP1412492A2 Regulator of calcineurin |
| 04/28/2004 | EP1412477A2 GPCs AS MODIFIERS OF THE IRRTK AND P21 PATHWAYS AND METHODS OF USE |
| 04/28/2004 | EP1412378A1 Aptamers and antiaptamers |
| 04/28/2004 | EP1412371A1 IN VIVO PRODUCTION OF SMALL INTERFERING RNAs THAT MEDIATE GENE SILENCING |
| 04/28/2004 | EP1412370A1 Nucleoside pyrophosphate and triphosphate analogs and related compounds as therapeutic agents |
| 04/28/2004 | EP1412368A2 Sugar derivatives of hydromorphone, dihydromorphine and dihydroisomorphine, compositions thereof and uses for treating or preventing pain |
| 04/28/2004 | EP1412366A1 Compounds for use as surfactants |
| 04/28/2004 | EP1412364A1 Platelet adp receptor inhibitors |
| 04/28/2004 | EP1412363A1 Gonadotropin-releasing hormone receptor antagonists |
| 04/28/2004 | EP1412362A1 Chemical compounds |
| 04/28/2004 | EP1412361A1 Substituted 5,6,6a,11b-tetrahydro-7-oxa-5-aza-benzo[c]fluorene-6-carboxylic acid derivatives serving as nmda antagonists |
| 04/28/2004 | EP1412360A1 COMBINATION THERAPY OF AN SODm AND A CORTICOSTEROID FOR PREVENTION AND/OR TREATMENT OF INFLAMMATORY DISEASE |
| 04/28/2004 | EP1412357A1 Beta-amino tetrahydroimidazo(1,2-a)pyrazines and tetrahydrotriazolo(4,3-a)pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
| 04/28/2004 | EP1412355A1 New pyrazolo(3,4-d)pyrimidines inhibiting h. pylori infections |
| 04/28/2004 | EP1412354A1 DERIVATIVES OF TRIAZOLYL-IMIDAZOPYRIDINE AND OF THE TRIAZOLYLPURINES USEFUL AS LIGANDS OF THE ADENOSINE A 2a? RECEPTOR AND THEIR USE AS MEDICAMENTS |
| 04/28/2004 | EP1412353A1 Imidazopyridinones as p38 map kinase inhibitors |
| 04/28/2004 | EP1412352A1 8-methoxy-(1,2,4)triazolo(1,5-a)pyridine derivatives and their use as adenosine receptor ligands |
| 04/28/2004 | EP1412349A2 Piperazine oxyquinoline (naphthaline) platelet adenosine diphosphate receptor antagonists |
| 04/28/2004 | EP1412343A1 New compounds, which are potent inhibitors of na+/ca2+ exchange mechanism and are useful in the treatment of arrhythmias |
| 04/28/2004 | EP1412341A1 Process for the preparation of racemic citalopram and/or s- or r-citalopram by separation of a mixture of r- and s-citalopram |
| 04/28/2004 | EP1412338A1 1,3,5-triazine-2,4,6-triones, preparation and use as gonadotropin-releasing hormone receptor antagonists |
| 04/28/2004 | EP1412337A1 Azole compounds as anti-fungal agents |
| 04/28/2004 | EP1412332A1 Quinoline derivatives and use thereof as antitumor agents |
| 04/28/2004 | EP1412330A1 Piperidine derivatives useful as modulators of chemokine receptor activity |
| 04/28/2004 | EP1412327A2 Inhibitors of protein kinase for the treatment of disease |
| 04/28/2004 | EP1412326A1 Butyric acid derivatives |
| 04/28/2004 | EP1412325A1 Substituted sulfonamide compounds, process for their use as medicament for the treatment of cns disorders, obesity and type ii diabetes |
| 04/28/2004 | EP1412324A2 Amino acid conjugates providing for sustained systemic concentrations of gaba analogues |
| 04/28/2004 | EP1412322A2 Protected 3.5-dihydroxy-2.2-dimethyl-valeroamides for the synthesis of epothilone and derivatives and method for the production and use thereof |
| 04/28/2004 | EP1412320A1 Linked cyclitols and their polysulfated derivatives |
| 04/28/2004 | EP1412317A1 Retinoid derivatives with antiangiogenic, antitumor and proapoptotic activities |
| 04/28/2004 | EP1412311A1 Novel treatment of adrenocortical hypersecretion and tumour growth |
| 04/28/2004 | EP1412029A2 Combinations comprising epothilones and pharmaceutical uses thereof |
| 04/28/2004 | EP1412028A1 Tetrahydroindolone and purine derivatives linked to arylpiperazines |
| 04/28/2004 | EP1411993A2 Radiolabeled irreversible inhibitors of epidermal growth factor receptor tyrosine kinase and their use in radioimaging and radiotherapy |
| 04/28/2004 | EP1411988A1 Mixed complexes for masking the taste of bitter active substances |
| 04/28/2004 | EP1411986A1 Composition for epigallocatechin gallate |
| 04/28/2004 | EP1411985A1 Treatment of parasitic disease |
| 04/28/2004 | EP1411984A2 Combination medicament for treatment of neoplastic diseases which contains cyanoguanidine ikk inhibitors and a second anti-neoplastic drug |
| 04/28/2004 | EP1411980A2 Uses of dc-sign and dc-signr for inhibiting hepatitis c virus infection |
| 04/28/2004 | EP1411979A1 Vaccine comprising gp120 and nef and/or tat for the immunisation against hiv |